U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H12N2O2
Molecular Weight 228.2466
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of OZAGREL

SMILES

OC(=O)\C=C\C1=CC=C(CN2C=CN=C2)C=C1

InChI

InChIKey=SHZKQBHERIJWAO-AATRIKPKSA-N
InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+

HIDE SMILES / InChI
Molecular Formula C13H12N2O2
Molecular Weight 228.2466
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

Ozagrel is a thromboxane A2 synthesis inhibitor used for the treatment of cerebral vasospasm and asthma due to its antiplatelet and anti-inflammation properties.

CNS Activity

CNS Penetrant
2,554

Originator

Kinex Pharmaceuticals| Ono Pharmaceutical
4

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
Thromboxane-A synthase
21
Inhibitor
8,297
 11.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Bronchial asthma
50
 Palliative
Approved
8,429
DOMENAN
Cerebral vasospasm
9
 Primary
Approved
8,429
XANBON

PubMed

Patents

20050009896
4
CN102429903 A
4
CN102626388 B
4
CN102633723 A
4
JPS57131769A
4
US20090247600 A1
4

Sample Use Guides

In Vivo Use Guide
1 tablet (200 mg of the active ingredient) at a time, twice a day after breakfast and before bedtime (for asthma). Intravenous infusion of 80mg, twice a day, solute in 500ml normal saline or 5% glucose solution (cerebral vasospasm).
Route of Administration: Other
In Vitro Use Guide
The influence of ozagrel on platelets aggregation was investigated. Platelet aggregation which was induced by ADP (5 uM) was inhibited by ozagrel. This inhibition was dependent on the concentration of the drug and was significant at 10(−6)–10(−3) M.
Substance Class Chemical
Record UNII
L256JB984D
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966